[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620913":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":38,"collaborators":42,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":10,"eligibilityCriteria":49,"healthyVolunteers":46,"sex":50,"minAge":51,"maxAge":10,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"NTM-PD cohort",null,"This cohort includes adults (≥18 years) with confirmed or suspected nontuberculous mycobacterial pulmonary disease (NTM-PD) in whom active pulmonary tuberculosis has been excluded and who are undergoing bronchoscopy as part of routine clinical care. Participants receive standard-of-care evaluation and management according to established NTM clinical guidelines. There are no experimental interventions assigned in this study. Residual bronchoalveolar lavage fluid remaining after clinically indicated testing is used for immunologic analyses, including flow cytometric assessment of inhibitory and exhausted T-cell subsets. Clinical data, nutritional status, imaging findings, and laboratory results are collected prospectively, and participants are followed longitudinally to assess time to initiation of antimicrobial treatment due to clinical disease progression and other clinically relevant outcomes.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Deog Kyeom Kim, MD, PhD","CONTACT","+82-2-870-2228","kimdkmd@gmail.com",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Heemoon Park, MD","+82-2-870-3439","coramdeo33@gmail.com",[23],{"facility":24,"status":10,"city":25,"state":26,"zip":27,"country":28,"countryCode":10,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"SMG-SNU Boramae Medical Center","Seoul","Dongjak-gu","07061","South Korea",{"type":30,"coordinates":31},"Point",[32,33],126.9784,37.566,{"lat":33,"lon":32},[36,37],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Deog Kyeom Kim","Clinical Professor, Department of Pulmonary and Critical Care Medicine, SMG-SNU Boramae Medical Center",[43],{"name":24,"class":6},"100620913","association-of-nutrition-and-t-cell-immune-activity-with-disease-progression-in-nontuberculous-mycobacterial-pulmonary-disease-100620913",false,"NCT07363798","Association of Nutrition and T Cell Immune Activity With Disease Progression in Nontuberculous Mycobacterial Pulmonary Disease","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Confirmed or suspected nontuberculous mycobacterial pulmonary disease\n* Active pulmonary tuberculosis excluded by standard microbiologic testing\n* Undergoing bronchoscopy as part of routine clinical evaluation or disease monitoring\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Active pulmonary tuberculosis confirmed by microbiologic testing\n* Positive latent tuberculosis infection test\n* Current active malignancy requiring treatment\n* History of solid organ transplantation or hematopoietic stem cell transplantation\n* Use of systemic immunosuppressive medications\n* Diagnosis of autoimmune disease\n* Use of biologic agents or planned initiation of biologic therapy\n* Acute lower respiratory tract infection requiring treatment within 4 weeks prior to bronchoscopy\n* Pregnancy","ALL","18 Years",{"count":53,"type":54},50,"ESTIMATED","2 Years","OBSERVATIONAL","Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a chronic lung infection caused by environmental mycobacteria. The clinical course of NTM-PD varies widely among patients. Some individuals remain stable for long periods without treatment, while others experience worsening lung disease that requires antibiotic therapy or may lead to death. Currently available clinical tools are limited in their ability to predict which patients will experience disease progression.\n\nThis observational study aims to better understand how the body's immune response and nutritional status are related to disease progression in adults with confirmed or suspected NTM-PD. In particular, the study focuses on T cells, a type of immune cell that plays an important role in controlling mycobacterial infections. Prior research suggests that impaired T-cell function may contribute to disease progression in NTM-PD, but most studies have relied on blood samples rather than immune cells from the lung, where the infection occurs.\n\nIn this study, immune cells obtained from bronchoalveolar lavage fluid during clinically indicated bronchoscopy will be analyzed to assess inhibitory and exhausted T-cell profiles in the lung. In addition, systemic T-cell function will be evaluated using the mitogen response from the QuantiFERON-TB Gold Plus blood test. Nutritional status and body composition will also be assessed, as poor nutrition is known to affect immune function and disease outcomes.\n\nParticipants will be followed over time as part of routine clinical care. The primary outcome of the study is the time from enrollment to the initiation of antibiotic treatment due to clinical disease progression. Secondary outcomes include identifying immune predictors of treatment initiation, examining the relationship between nutritional status and immune activity, evaluating changes in body composition and immune markers with disease progression, and determining whether immune and nutritional measures improve prediction of mortality beyond established clinical risk scores.\n\nBy integrating lung immune profiling, blood-based immune testing, nutritional assessment, and clinical data, this study seeks to improve risk stratification in NTM-PD. The results may help identify patients at higher risk for disease progression and poor outcomes, support more personalized monitoring strategies, and inform future studies targeting immune and nutritional pathways in NTM-PD.",[59,60],"Nontuberculous Mycobacterial Pulmonary Disease","Nontuberculous Mycobacterial Lung Disease",[62,63,64,65,66],"Nontuberculous mycobacterial pulmonary disease","Bronchoalveolar lavage","T cell exhaustion","Disease progression","Nutritional status","NOT_YET_RECRUITING","2026-01-14",{"date":70,"type":71},"2026-01-23","ACTUAL",{"date":73,"type":54},"2026-01",{"date":75,"type":54},"2027-12-31",{"name":5,"class":6},1]